Acral erythema has been reported in patients receiving sustained dosing (or those who could use prolonged exposure) of the cytotoxic drugs fluorouracil, capecitabine, cytarabine, sorafenib, sunitinib, and pegylated liposomal doxorubicin.
Tingling and/or numbness (aka paresthesias) in the palms and soles are the first symptoms, which then evolve into painful well-demarcated symmetrical swelling and red plaques, followed by peeling and symptom resolution.
Acral erythema, with similar clinical and histological features, can also occur after bone marrow transplant due to dermatologic manifestations of graft vs. host disease.
Symptoms generally resolve 1 to 2 weeks after discontinuing chemotherapy. Results from small clinical studies suggest that corticosteroids may be helpful in relieving symptoms, and that frequent applications of emollients to the hands and feet may help prevent the disorder. The offending anticancer drug may be reintroduced at lower doses once the side effects have abated.
Acral erythema is an adverse drug reaction to chemotherapy that can occur days to months after a patient begins treatment and results in reddening, swelling and desquamation of the skin, often of the palms and soles. The syndrome is also referred to as hand-foot syndrome, palmar-plantar erythrodysesthesia, and Burgdorf’s reaction.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|